The company announced the initiation of RAPIDe-3, the Phase 3 clinical trial evaluating the efficacy and safety of deucrictibant immediate-release capsule (PHVS416) for the treatment of HAE attacks.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PHVS:
- Pharvaris files to sell 5.55M ordinary shares for holders
- Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses
- Pharvaris to Participate in the Leerink Global Biopharma Conference 2024
- Pharvaris’ deucrictibant shows positive results in HAE attacks
- Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting
